Short Interest in Pharming Group (NASDAQ:PHAR) Rises By 107.1%

Pharming Group (NASDAQ:PHAR) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,800 shares, a growth of 107.1% from the February 28th total of 2,800 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 6,700 shares, the days-to-cover ratio is presently 0.9 days.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PHAR. Jefferies Financial Group initiated coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th. Finally, Oppenheimer lifted their price target on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th.

Pharming Group Trading Down 3.2 %

Shares of Pharming Group stock traded down $0.27 during trading hours on Friday, reaching $8.38. The stock had a trading volume of 5,632 shares, compared to its average volume of 6,202. The firm has a market capitalization of $569.83 million, a price-to-earnings ratio of -32.22 and a beta of -0.10. Pharming Group has a 1 year low of $6.65 and a 1 year high of $11.30. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a 50 day simple moving average of $8.80 and a two-hundred day simple moving average of $8.66.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. As a group, equities research analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.